Abstract
Over the last 5 years I have been coordinating a graduate course on genomic technologies and their applications in medicine. The course is offered to graduate students in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. In attending the diverse lectures, I came to better understand the burgeoning field of “personalized” or “precision” medicine (PM) and its current status and future prospects. Below, I provide my personal views on this topic.
Author contributions: The author has accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Pulciani S, Di Lonardo A, Fagnani C, Taruscio D. P4 medicine versus Hippocrates. Ann 1st Super Sanita 2017;53:185–91.Search in Google Scholar
2. Goldman JM, Galey GQ. Chronic myelogenous leukemia-a brief history. In: Myeloproliferative disorders. Hematologic malignancies. Berlin: Springer, 2007:1–13.10.1007/978-3-540-34506-0Search in Google Scholar
3. Balachandran VP, DeMatteo RP. GIST tumors: who should get imatinib and for how long? Adv Surg 2014;48:165–83.10.1016/j.yasu.2014.05.014Search in Google Scholar
4. Anonymous. A triumph of perseverance over interference. Nat Biotechnol 2018;36:775.10.1038/nbt.4255Search in Google Scholar
5. Rittenhouse H, Blasé A, Shamel B, Schalken J, Groskopf J. The long and winding road to FDA approval of a novel prostate cancer test: our story. Clin Chem 2013;59:32–4.10.1373/clinchem.2012.198739Search in Google Scholar
6. Sheridan C. Roche splashes $2.4 billion on Foundation Medicine’s cancer platform. Nat Biotechnol 2018;36:779–80.10.1038/nbt0918-779Search in Google Scholar
7. Liu YC, Ma Y, An N, Sun P, Wang Y, Sun C. Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer. Medicine (Baltimore) 2019;98:e17262.10.1097/MD.0000000000017262Search in Google Scholar
8. Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015;16:1324–34.10.1016/S1470-2045(15)00188-6Search in Google Scholar
9. Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. J Am Med Assoc Oncol 2018;4:1093–8.10.1001/jamaoncol.2018.1660Search in Google Scholar PubMed PubMed Central
10. Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;23:703–13.10.1038/nm.4333Search in Google Scholar PubMed PubMed Central
11. Bian S, Hou Y, Zhou X, Li X, Yong J, Wang Y, et al. Single-cell multiomics sequencing and analyses of human colorectal cancer. Science 2018;362:1060–3.10.1126/science.aao3791Search in Google Scholar PubMed
12. Senn S. Statistical pitfalls of personalized medicine. Nature 2018;563:619–21.10.1038/d41586-018-07535-2Search in Google Scholar PubMed
13. Allison J. Quoted in Nat Biotechnol 2018;36:781. https://www.biocentury.com/bc-innovations/tools-techniques/2018-07-19/how-md-anderson-using-its-access-clinical-samples-home-.10.1038/nbt0918-781bSearch in Google Scholar PubMed
14. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 2018;36:1668–74.10.1200/JCO.2017.75.6270Search in Google Scholar PubMed
15. Aggrawal A, Ginsburg O, Fojo T. Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US. J Cancer Policy 2014;2:1–11.10.1016/j.jcpo.2014.02.002Search in Google Scholar
16. Song M, Vogelstein B, Giovannucci EL, Wilett WC, Tomasetti C. Cancer prevention: Molecular and epidemiologic consensus. Science 2018;361:1317–8.10.1126/science.aau3830Search in Google Scholar PubMed PubMed Central
17. Rodland KD, Piehowski P, Smith RD. Moonshot objectives: Catalyze new scientific breakthroughs-Proteogenomics. Cancer J 2018;24:121–5.10.1097/PPO.0000000000000315Search in Google Scholar PubMed PubMed Central
18. Walker SP. The ROC curve redefined-optimizing sensitivity (and specificity) to the lived reality of cancer. N Engl J Med 2019;380:1594–5.10.1056/NEJMp1814951Search in Google Scholar PubMed
©2020 Walter de Gruyter GmbH, Berlin/Boston
